C M Mink
Overview
Explore the profile of C M Mink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tondella M, Carlone G, Messonnier N, Quinn C, Meade B, Burns D, et al.
Vaccine
. 2008 Dec;
27(6):803-14.
PMID: 19071179
An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the...
2.
Lottenbach K, Mink C, Barenkamp S, Anderson E, Homan S, Powers D
Infect Immun
. 1999 Aug;
67(9):4935-8.
PMID: 10456954
Immunoglobulin G (IgG) subclass antibody responses to pneumococcal vaccines were determined for human subjects in four age groups. The ratios of IgG1/IgG2 antibody concentrations declined with advancing age for all...
3.
Keitel W, Muenz L, Decker M, Englund J, Mink C, Blumberg D, et al.
J Infect Dis
. 1999 Jul;
180(2):397-403.
PMID: 10395855
The safety and immunogenicity of 5 acellular pertussis vaccines (ACVs) were compared in a multicenter, randomized, double-blind trial. A total of 481 healthy adults were given a single intramuscular booster...
4.
Weiss A, Mobberley P, Fernandez R, Mink C
Infect Immun
. 1999 Feb;
67(3):1424-31.
PMID: 10024590
The Bordetella pertussis BrkA protein protects against the bactericidal activity of complement and antibody; however, some individuals mount an immune response that overcomes this bacterial defense. To further characterize this...
5.
Powers D, Anderson E, LOTTENBACH K, Mink C
J Infect Dis
. 1996 Apr;
173(4):1014-8.
PMID: 8603942
Healthy adults > or = 50 years old were immunized with either pentavalent Corynebacterium diphtheriae C7 (beta197) cross-reactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 microgram each of capsular...
6.
Meade B, Lynn F, Reed G, Mink C, Romani T, Deforest A, et al.
Pediatrics
. 1995 Sep;
96(3 Pt 2):595-600.
PMID: 7659484
Objective: To examine the relationships between functional assays and antigen-specific enzyme immunoassays in sera from a multicenter trial of 13 different experimental acellular pertussis vaccines and 2 licensed whole-cell vaccines,...
7.
Anderson E, Bowers T, Mink C, Kennedy D, Belshe R, Harakeh H, et al.
Infect Immun
. 1994 Aug;
62(8):3391-5.
PMID: 8039909
A meningococcal vaccine containing group A and C polysaccharides conjugated to CRM197 was evaluated in 50 adults. Vaccinees were entered into one of five groups: 30 adults received a single...
8.
Mink C, Obrien C, Wassilak S, Deforest A, Meade B
Infect Immun
. 1994 Mar;
62(3):1118-20.
PMID: 7509316
Elevated agglutinin titers have been shown to correlate with protection from disease following whole-cell pertussis vaccination, but the isotype and antigen specificity of human agglutinating antibodies is unknown. In 13...
9.
Anderson E, Mink C, BERLIN B, Shih C, TUNG F, Belshe R
Vaccine
. 1994 Jan;
12(1):28-31.
PMID: 8303937
Two acellular pertussis vaccines, one containing only LPF toxoid (25 micrograms) and the other containing LPF toxoid (25 micrograms) and FHA (25 micrograms) and each combined with diphtheria and tetanus...
10.
Mulholland E, Ahonkhai V, Greenwood A, Jonas L, Lukacs L, Mink C, et al.
Pediatr Infect Dis J
. 1993 Aug;
12(8):632-7.
PMID: 8414774
To ensure compliance and to reduce costs it is important, especially in less developed countries, that programs of child immunization should require as few clinic attendances and as few injections...